Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system
- Autores
- Pagnotta, Priscila Ayelén; Melito, Viviana Alicia; Zuccoli, Johanna Romina; Parera, Victoria Estela; Buzaleh, Ana Maria
- Año de publicación
- 2024
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- Acute Intermittent Porphyria (AIP) is a metabolic disease in which the mutation in Porphobilinogen deaminase is not enough for the manifestation of the symptoms. Previous experimental results have shown that alternative variants in genes of ABC drug transporter (ABCB1: rs1045642, rs2032582, rs1128503; ABCG2: rs2231137) and NR1I2 gene (rs12721613), regulator of ABC transcription, could be involved in the onset of AIP. The aim was to investigate further the influence of ABCB1, ABCG2 and NR1I2 on AIP onset in relation to porphyrinogenic drugs employing bioinformatics tools. For this purpose, three SNVs of ABCB1 (rs1045642, rs1128503, rs20325822), two SNVs of ABCG2 (rs2231137, rs2231) and four SNVs of NR1I2 (rs12721613, rs2472677, rs12721607, rs12721608) were evaluated using different databases: gnomAD; UniProt; GenBank; PharmGKB, association between genetic variants, drugs and clinical manifestations; Gene Expression Omnibus, expression arrays; PreADMET and SwissADME, to estimate whether drugs are substrates/inhibitors of different transporters. Allele frequencies varied among different geographic regions and ethnicities, reinforcing the relevance of local control group analysis. For NR1I2 gene, T allele of rs2472677 was associated with a phenotype of toxicity, an altered metabolism and/or a different efficacy for drugs contraindicated in AIP (Isoniazid, Rifampicin and Efavirenz). Considering models to infer liver toxicity, Rifampicin induced down expression of ABCB1 and 8 CYP genes, including CYP3A4, in primary culture of human hepatocytes (GSE139896); Isoniazid caused differential expression of 11 ABC genes (27.3% down expressed) and 18 CYP genes (61.1% down expressed) in a human liver cancer cell line (GSE168473). Analyzing Free Wilson’s equations to find possible drugs to replace those insecure for AIP patients, some derivatives of Thiofeno[3,2]pyrimidine would represent therapeutic alternatives to Efavirenz. These derivatives would have a differential action as substrates/inhibitors of ABCB1 transporter and CYP. Associations between non-wild type variants of ABCB1 and ABCG2, drugs contraindicated in AIP and a phenotype of toxicity or alteration of metabolism were also found: rs1045642, rs1128503 and rs1128503 for ABCB1 (13, 2, and 2 xenobiotics, respectively); and rs2231137 and rs2231142 for ABCG2 (2 and 10 xenobiotics, respectively). In conclusion, it was observed that contraindicated drugs for AIP patients are associated with toxicity and a differential metabolism in the presence of the studied variants. In turn, these drugs alter the gene expression of drug metabolizing and transporting systems. Bioinformatics tools are a valuable complement for experimental findings and for exploring new approaches and would be of relevance in personalized medicine and pharmacogenetics, a topic of upmost relevance in the pathophysiology of Hepatic Porphyrias.
Fil: Pagnotta, Priscila Ayelén. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Melito, Viviana Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina
Fil: Zuccoli, Johanna Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina
Fil: Parera, Victoria Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina
Fil: Buzaleh, Ana Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina
International Congress of Porphyrins and Porphyrias
Pamplona
España
International Porphyria Network - Materia
-
PORPHYRIA
BIOINFORMATIC
PORPHYRINOGENIC XENOBIOTICS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/263962
Ver los metadatos del registro completo
id |
CONICETDig_364ff8d4cd9fbcd38dcce5511fefa52f |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/263962 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter systemPagnotta, Priscila AyelénMelito, Viviana AliciaZuccoli, Johanna RominaParera, Victoria EstelaBuzaleh, Ana MariaPORPHYRIABIOINFORMATICPORPHYRINOGENIC XENOBIOTICShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Acute Intermittent Porphyria (AIP) is a metabolic disease in which the mutation in Porphobilinogen deaminase is not enough for the manifestation of the symptoms. Previous experimental results have shown that alternative variants in genes of ABC drug transporter (ABCB1: rs1045642, rs2032582, rs1128503; ABCG2: rs2231137) and NR1I2 gene (rs12721613), regulator of ABC transcription, could be involved in the onset of AIP. The aim was to investigate further the influence of ABCB1, ABCG2 and NR1I2 on AIP onset in relation to porphyrinogenic drugs employing bioinformatics tools. For this purpose, three SNVs of ABCB1 (rs1045642, rs1128503, rs20325822), two SNVs of ABCG2 (rs2231137, rs2231) and four SNVs of NR1I2 (rs12721613, rs2472677, rs12721607, rs12721608) were evaluated using different databases: gnomAD; UniProt; GenBank; PharmGKB, association between genetic variants, drugs and clinical manifestations; Gene Expression Omnibus, expression arrays; PreADMET and SwissADME, to estimate whether drugs are substrates/inhibitors of different transporters. Allele frequencies varied among different geographic regions and ethnicities, reinforcing the relevance of local control group analysis. For NR1I2 gene, T allele of rs2472677 was associated with a phenotype of toxicity, an altered metabolism and/or a different efficacy for drugs contraindicated in AIP (Isoniazid, Rifampicin and Efavirenz). Considering models to infer liver toxicity, Rifampicin induced down expression of ABCB1 and 8 CYP genes, including CYP3A4, in primary culture of human hepatocytes (GSE139896); Isoniazid caused differential expression of 11 ABC genes (27.3% down expressed) and 18 CYP genes (61.1% down expressed) in a human liver cancer cell line (GSE168473). Analyzing Free Wilson’s equations to find possible drugs to replace those insecure for AIP patients, some derivatives of Thiofeno[3,2]pyrimidine would represent therapeutic alternatives to Efavirenz. These derivatives would have a differential action as substrates/inhibitors of ABCB1 transporter and CYP. Associations between non-wild type variants of ABCB1 and ABCG2, drugs contraindicated in AIP and a phenotype of toxicity or alteration of metabolism were also found: rs1045642, rs1128503 and rs1128503 for ABCB1 (13, 2, and 2 xenobiotics, respectively); and rs2231137 and rs2231142 for ABCG2 (2 and 10 xenobiotics, respectively). In conclusion, it was observed that contraindicated drugs for AIP patients are associated with toxicity and a differential metabolism in the presence of the studied variants. In turn, these drugs alter the gene expression of drug metabolizing and transporting systems. Bioinformatics tools are a valuable complement for experimental findings and for exploring new approaches and would be of relevance in personalized medicine and pharmacogenetics, a topic of upmost relevance in the pathophysiology of Hepatic Porphyrias.Fil: Pagnotta, Priscila Ayelén. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Melito, Viviana Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; ArgentinaFil: Zuccoli, Johanna Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; ArgentinaFil: Parera, Victoria Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; ArgentinaFil: Buzaleh, Ana Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; ArgentinaInternational Congress of Porphyrins and PorphyriasPamplonaEspañaInternational Porphyria NetworkBMJ Publishing Group2024info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectCongresoJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/263962Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system; International Congress of Porphyrins and Porphyrias; Pamplona; España; 2024; 5-62054-4774CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://bmjopengastro.bmj.com/content/11/Suppl_1/A2.2Internacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:14:45Zoai:ri.conicet.gov.ar:11336/263962instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:14:46.001CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system |
title |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system |
spellingShingle |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system Pagnotta, Priscila Ayelén PORPHYRIA BIOINFORMATIC PORPHYRINOGENIC XENOBIOTICS |
title_short |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system |
title_full |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system |
title_fullStr |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system |
title_full_unstemmed |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system |
title_sort |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system |
dc.creator.none.fl_str_mv |
Pagnotta, Priscila Ayelén Melito, Viviana Alicia Zuccoli, Johanna Romina Parera, Victoria Estela Buzaleh, Ana Maria |
author |
Pagnotta, Priscila Ayelén |
author_facet |
Pagnotta, Priscila Ayelén Melito, Viviana Alicia Zuccoli, Johanna Romina Parera, Victoria Estela Buzaleh, Ana Maria |
author_role |
author |
author2 |
Melito, Viviana Alicia Zuccoli, Johanna Romina Parera, Victoria Estela Buzaleh, Ana Maria |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
PORPHYRIA BIOINFORMATIC PORPHYRINOGENIC XENOBIOTICS |
topic |
PORPHYRIA BIOINFORMATIC PORPHYRINOGENIC XENOBIOTICS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Acute Intermittent Porphyria (AIP) is a metabolic disease in which the mutation in Porphobilinogen deaminase is not enough for the manifestation of the symptoms. Previous experimental results have shown that alternative variants in genes of ABC drug transporter (ABCB1: rs1045642, rs2032582, rs1128503; ABCG2: rs2231137) and NR1I2 gene (rs12721613), regulator of ABC transcription, could be involved in the onset of AIP. The aim was to investigate further the influence of ABCB1, ABCG2 and NR1I2 on AIP onset in relation to porphyrinogenic drugs employing bioinformatics tools. For this purpose, three SNVs of ABCB1 (rs1045642, rs1128503, rs20325822), two SNVs of ABCG2 (rs2231137, rs2231) and four SNVs of NR1I2 (rs12721613, rs2472677, rs12721607, rs12721608) were evaluated using different databases: gnomAD; UniProt; GenBank; PharmGKB, association between genetic variants, drugs and clinical manifestations; Gene Expression Omnibus, expression arrays; PreADMET and SwissADME, to estimate whether drugs are substrates/inhibitors of different transporters. Allele frequencies varied among different geographic regions and ethnicities, reinforcing the relevance of local control group analysis. For NR1I2 gene, T allele of rs2472677 was associated with a phenotype of toxicity, an altered metabolism and/or a different efficacy for drugs contraindicated in AIP (Isoniazid, Rifampicin and Efavirenz). Considering models to infer liver toxicity, Rifampicin induced down expression of ABCB1 and 8 CYP genes, including CYP3A4, in primary culture of human hepatocytes (GSE139896); Isoniazid caused differential expression of 11 ABC genes (27.3% down expressed) and 18 CYP genes (61.1% down expressed) in a human liver cancer cell line (GSE168473). Analyzing Free Wilson’s equations to find possible drugs to replace those insecure for AIP patients, some derivatives of Thiofeno[3,2]pyrimidine would represent therapeutic alternatives to Efavirenz. These derivatives would have a differential action as substrates/inhibitors of ABCB1 transporter and CYP. Associations between non-wild type variants of ABCB1 and ABCG2, drugs contraindicated in AIP and a phenotype of toxicity or alteration of metabolism were also found: rs1045642, rs1128503 and rs1128503 for ABCB1 (13, 2, and 2 xenobiotics, respectively); and rs2231137 and rs2231142 for ABCG2 (2 and 10 xenobiotics, respectively). In conclusion, it was observed that contraindicated drugs for AIP patients are associated with toxicity and a differential metabolism in the presence of the studied variants. In turn, these drugs alter the gene expression of drug metabolizing and transporting systems. Bioinformatics tools are a valuable complement for experimental findings and for exploring new approaches and would be of relevance in personalized medicine and pharmacogenetics, a topic of upmost relevance in the pathophysiology of Hepatic Porphyrias. Fil: Pagnotta, Priscila Ayelén. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Melito, Viviana Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina Fil: Zuccoli, Johanna Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina Fil: Parera, Victoria Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina Fil: Buzaleh, Ana Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Investigaciones sobre Porfirinas y Porfirias. Universidad de Buenos Aires. Centro de Investigaciones sobre Porfirinas y Porfirias; Argentina International Congress of Porphyrins and Porphyrias Pamplona España International Porphyria Network |
description |
Acute Intermittent Porphyria (AIP) is a metabolic disease in which the mutation in Porphobilinogen deaminase is not enough for the manifestation of the symptoms. Previous experimental results have shown that alternative variants in genes of ABC drug transporter (ABCB1: rs1045642, rs2032582, rs1128503; ABCG2: rs2231137) and NR1I2 gene (rs12721613), regulator of ABC transcription, could be involved in the onset of AIP. The aim was to investigate further the influence of ABCB1, ABCG2 and NR1I2 on AIP onset in relation to porphyrinogenic drugs employing bioinformatics tools. For this purpose, three SNVs of ABCB1 (rs1045642, rs1128503, rs20325822), two SNVs of ABCG2 (rs2231137, rs2231) and four SNVs of NR1I2 (rs12721613, rs2472677, rs12721607, rs12721608) were evaluated using different databases: gnomAD; UniProt; GenBank; PharmGKB, association between genetic variants, drugs and clinical manifestations; Gene Expression Omnibus, expression arrays; PreADMET and SwissADME, to estimate whether drugs are substrates/inhibitors of different transporters. Allele frequencies varied among different geographic regions and ethnicities, reinforcing the relevance of local control group analysis. For NR1I2 gene, T allele of rs2472677 was associated with a phenotype of toxicity, an altered metabolism and/or a different efficacy for drugs contraindicated in AIP (Isoniazid, Rifampicin and Efavirenz). Considering models to infer liver toxicity, Rifampicin induced down expression of ABCB1 and 8 CYP genes, including CYP3A4, in primary culture of human hepatocytes (GSE139896); Isoniazid caused differential expression of 11 ABC genes (27.3% down expressed) and 18 CYP genes (61.1% down expressed) in a human liver cancer cell line (GSE168473). Analyzing Free Wilson’s equations to find possible drugs to replace those insecure for AIP patients, some derivatives of Thiofeno[3,2]pyrimidine would represent therapeutic alternatives to Efavirenz. These derivatives would have a differential action as substrates/inhibitors of ABCB1 transporter and CYP. Associations between non-wild type variants of ABCB1 and ABCG2, drugs contraindicated in AIP and a phenotype of toxicity or alteration of metabolism were also found: rs1045642, rs1128503 and rs1128503 for ABCB1 (13, 2, and 2 xenobiotics, respectively); and rs2231137 and rs2231142 for ABCG2 (2 and 10 xenobiotics, respectively). In conclusion, it was observed that contraindicated drugs for AIP patients are associated with toxicity and a differential metabolism in the presence of the studied variants. In turn, these drugs alter the gene expression of drug metabolizing and transporting systems. Bioinformatics tools are a valuable complement for experimental findings and for exploring new approaches and would be of relevance in personalized medicine and pharmacogenetics, a topic of upmost relevance in the pathophysiology of Hepatic Porphyrias. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Congreso Journal http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
status_str |
publishedVersion |
format |
conferenceObject |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/263962 Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system; International Congress of Porphyrins and Porphyrias; Pamplona; España; 2024; 5-6 2054-4774 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/263962 |
identifier_str_mv |
Acute intermittent porphyria onset: bioinformatic and genetic analysis of porphyrinogenic xenobiotics and drugs transporter system; International Congress of Porphyrins and Porphyrias; Pamplona; España; 2024; 5-6 2054-4774 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://bmjopengastro.bmj.com/content/11/Suppl_1/A2.2 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.coverage.none.fl_str_mv |
Internacional |
dc.publisher.none.fl_str_mv |
BMJ Publishing Group |
publisher.none.fl_str_mv |
BMJ Publishing Group |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614078734008320 |
score |
13.070432 |